Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 7/20 | 0.55 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13042191 | 0.90 | SLC6A9 (0.54) | SLC7A5SLC6A9SLC6A4HTR1AHRH3 | |
| SCHEMBL27299983 | 0.90 | SLC6A4 (0.62) | SLC7A5SLC6A4HRH3KDM4EMEN1 | |
| SCHEMBL17278094 | 0.84 | SLC7A5 (0.71) | SLC7A5SLC6A9SLC6A4HTR1A | |
| SCHEMBL17280858 | 0.84 | SLC7A5 (0.71) | SLC7A5SLC6A9SLC6A4HTR1A | |
| SCHEMBL17280857 | 0.84 | SLC7A5 (0.71) | SLC7A5SLC6A9SLC6A4HTR1A | |
| SCHEMBL15257454 | 0.83 | SLC6A4 (0.68) | SLC6A4HRH3KDM4EMEN1NPC1 | |
| SCHEMBL17280831 | 0.83 | SLC7A5 (0.69) | SLC7A5SLC6A9SLC6A4HTR1A | |
| SCHEMBL10021745 | 0.83 | IGLV6-57 (0.51) | SLC7A5SLC6A9SLC6A4HTR1AHRH3 | |
| SCHEMBL4450767 | 0.83 | SLC6A4 (0.50) | SLC7A5SLC6A4HRH3KDM4EMEN1 | |
| SCHEMBL2776404 | 0.83 | SLC7A5 (0.53) | SLC7A5SLC6A9SLC6A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170007598-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2017-01-12 | — | — | US | disclosed |
| US-9238033-B2 | Pharmaceutical composition containing KW-6002 and fluoxetine or paroxentine | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-01-19 | — | — | US | disclosed |
| US-20150141452-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2015-05-21 | — | — | US | disclosed |
| US-8802596-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130237526-A1 | PHARMACEUTICAL COMPOSITION | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-09-12 | — | — | US | disclosed |
| US-8440678-B2 | Pharmaceutical composition | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | Sunovion Inc. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120010225-A1 | PHARMACEUTICAL COMPOSITION | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20120010232-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | OREXIGEN THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110060156-A1 | Pyruvate Derivatives with Neuroprotective Effect, Process for Preparing the Same and Pharmaceutical Composition Comprising the Same | S.H. PHARMA., LTD. (KR) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | SLC5A6, PNLIP, IPMK | SLC7A5 141/4885SLC6A9 472/4885SLC6A4 823/4885 |
| US-20150141452-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | MC4R, MC3R, MC5R | SLC7A5 4202/4885SLC6A9 4130/4885SLC6A4 978/4885 |
| US-20170007598-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | MC4R, MC3R, MC5R | SLC7A5 4202/4885SLC6A9 4130/4885SLC6A4 978/4885 |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | SLC7A5 1472/4885SLC6A9 3115/4885SLC6A4 65/4885 |
| US-20120010232-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | MC4R, MC3R, MC5R | SLC7A5 4202/4885SLC6A9 4130/4885SLC6A4 978/4885 |
| US-20120010225-A1 | PHARMACEUTICAL COMPOSITION | ADORA2A, HTR2C, HTR5A | SLC7A5 227/4885SLC6A9 1016/4885SLC6A4 39/4885 |
| US-20110060156-A1 | Pyruvate Derivatives with Neuroprotective Effect, Process for Preparing the Same and Pharmaceutical Composition Comprising the Same | PC, PDK1, PDK2 | SLC7A5 2103/4885SLC6A9 1231/4885SLC6A4 1528/4885 |
| US-20130237526-A1 | PHARMACEUTICAL COMPOSITION | ADORA2A, HTR2C, HTR5A | SLC7A5 227/4885SLC6A9 1016/4885SLC6A4 39/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | SLC7A5 4623/4885SLC6A9 4836/4885SLC6A4 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.